Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Gene Mutation Might Determine Proper Dosage

May 11, 2010 6:51 am | News | Comments

A tiny gene mutation in human liver cells could one day influence how high or low a dose patients need of about half of the clinically used drugs on the market, new research suggests.


Researchers Discover TB Drug Target

May 11, 2010 6:46 am | News | Comments

The cause of tuberculosis is Mycobacterium tuberculosis (Mtb), a slow-growing aerobic bacterium that divides every 16 to 20 hours.


Cell Signaling May Allow Better Vaccines

May 11, 2010 6:41 am | News | Comments

Inducing cellular immunity as a means to protect against influenza virus is the focus of several laboratories at the Trudeau Institute.


Merck Settles Zetia Suit

May 11, 2010 6:36 am | News | Comments

Merck & Co. said it settled a patent dispute with Glenmark Pharmaceuticals on the cholesterol drug Zetia, one of its best-selling products.


Gilead Buying Back $5B of Stock

May 11, 2010 6:32 am | News | Comments

Gilead Sciences, Inc. announced that the company's board of directors has authorized the repurchase of up to $5 billion of the company's common stock through May 2013.


Abbott Targeting Emerging Markets

May 11, 2010 6:28 am | News | Comments

Abbott Laboratories will license at least 24 products in emerging markets through a new unit created to boost sales outside of the U.S., the drug and medical device maker said.


Schering-Plough Integration With Merck On Track

May 11, 2010 6:24 am | News | Comments

Drugmaker Merck & Co. said that its integration of Schering Plough Corp. is off to a good start, with sales and other operations already combined in the top 20 companies where they operate.


HTFC Screening System

May 10, 2010 8:14 am | Product Releases | Comments

IntelliCyt Corp., a provider of innovative high throughput cell and bead-based screening products for drug discovery and life science research, introduced its new High Throughput Flow Cytometry – HTFC Screening System.


Artel Expands to German-Speaking Countries

May 10, 2010 8:03 am | News | Comments

In a bid to meet growing international demand for its liquid handling quality assurance products and services, Artel is expanding into Germany, Switzerland, and Austria, where it will begin offering direct sales and distribution of its Multichannel Verification System and Pipette Calibration System.


Evotec Partnered With Genentech

May 10, 2010 7:56 am | News | Comments

Evotec AG announced that it has entered into a multi-year integrated drug discovery alliance with Genentech Inc., a wholly owned member of the Roche Group, to discover novel small molecule therapeutics.


ADDF Awards Grant to Amicus Therapeutics

May 10, 2010 7:50 am | News | Comments

The Alzheimer’s Drug Discovery Foundation (ADDF) has awarded a grant of $210,300 to Amicus Therapeutics to evaluate small-molecule, orally delivered pharmacological chaperone compounds as a novel approach for treating Alzheimer’s disease.


Canadian Scientists Develop Mouse Grimace Scale

May 10, 2010 7:43 am | News | Comments

A new study by researchers from McGill University and the University of British Columbia shows that mice, like humans, express pain through facial expressions.


Scripps Researchers Find Key to Gaucher Treatment

May 10, 2010 7:37 am | News | Comments

In findings that advance scientists' understanding of a whole class of inherited disorders, The Scripps Research Institute has shed light on a mechanism that enables a potential treatment for Gaucher's disease and other lysosomal storage diseases.


Pramipexole Improves Mood in Parkinson's Patients

May 10, 2010 7:31 am | News | Comments

Pramipexole, a dopamine agonist, improves depressive symptoms in patients with Parkinson's disease (PD), and has the potential to become an important antidepressant treatment for these patients.


Phase 2 VB-201 Trial Successful

May 10, 2010 7:22 am | News | Comments

VBL Therapeutics announced positive preclinical results evaluating VB-201 for the treatment of psoriasis. VB-201 is a first-in-class, orally administered immune response modifier expected to reduce inflammation by targeting key pro-inflammatory cytokines.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.